" class="no-js "lang="en-US"> Eleven Therapeutics - Medtech Alert
Friday, August 01, 2025
Eleven Therapeutics | Pharmtech Focus

Eleven Therapeutics

About Eleven Therapeutics

Eleven Therapeutics

Eleven Therapeutics ushers in the next generation of RNAi therapeutics by combining artificial intelligence (AI), massively parallel functional assays, and combinatorial chemistry. Its flagship invention features a new modality, dubbed SCSI-RNA™ (smart-combinatorial, small interfering RNA), a fully programmable molecule, rationally designed to address the delivery, durability, and efficacy challenges of any disease and biological target of interest. Founded in 2020 by a group of globally-leading, interdisciplinary scientists, Eleven Therapeutics brings new RNAi therapeutics for patients in need by capitalising on some of the world’s best pools of talent through its three collaborative hubs—in Cambridge, UKBoston, U.S.; and Tel Aviv, Israel. Eleven is currently focusing its development pipeline on siRNA treatments for a range of respiratory diseases.

Related Story

Eleven Therapeutics Announces $22 Million in Seed Funding

August 3 2022

Eleven Therapeutics, a biotechnology company leading the AI revolution in nucleic acid therapeutics, announced today […]